The global dry eye disease treatment devices market size is likely to be valued at US$1.4 billion in 2026, and is expected to reach US$2.5 billion by 2033, growing at a CAGR of 8.5% during the forecast period from 2026 to 2033, driven by rising global dry eye disease prevalence, growing awareness of device-based treatment options, and expanding adoption of thermal pulsation and light-based therapy technologies across hospitals, eye care clinics, and optometry practices.

Driver - Digital Screen Exposure and Aging Demographics

The rising global prevalence of dry eye disease (DED), fueled by aging populations and increasing digital device use, is a key driver of the dry eye disease treatment devices market. DED affects an estimated 5–50% of adults worldwide, depending on geographic region and diagnostic criteria. Its prevalence increases significantly with age and prolonged screen exposure, which reduces blink frequency and contributes to Meibomian gland dysfunction.

Average daily digital screen exposure among adults has increased substantially, particularly among office workers and younger populations, with hybrid work models maintaining high levels of digital exposure. Screen use reduces blink rates from about 15 blinks per minute during normal conversation to 5–7 blinks per minute, accelerating Meibomian gland atrophy and evaporative dry eye. In the U.S., a landmark study published in the American Journal of Ophthalmology estimated that around 16 million people have physician-diagnosed DED, while the actual number of affected individuals, including undiagnosed cases, is likely 2–3 times higher.

Restraint - Fragmented Diagnostic Standards and Underdiagnosis of Meibomian Gland Dysfunction

A major challenge limiting the growth of the dry eye disease treatment devices market is the underdiagnosis and misdiagnosis of Meibomian gland dysfunction (MGD) in routine eye care. Early-stage MGD often presents symptoms similar to aqueous-deficient dry eye, allergic conjunctivitis, and contact lens discomfort. As a result, many patients receive pharmacological treatment instead of undergoing device-based diagnosis and targeted thermal therapy.

According to the TFOS DEWS II Epidemiology Subcommittee, MGD affects approximately 39–68% of the population in epidemiological studies. However, clinical diagnosis rates remain significantly lower, highlighting the widespread underdiagnosis of the condition in routine practice.

Opportunity - Home-use Dry Eye Treatment Device Expansion and Digital Health Integration

The growing adoption of home-use thermal eyelid warming devices and digital health-enabled monitoring tools presents a significant opportunity for the dry eye disease treatment devices market. These solutions support patients who require ongoing maintenance therapy between office-based thermal pulsation or IPL treatments but have limited access to frequent clinical visits. Temperature-controlled heated eye masks and other home-use devices complement in-clinic treatments and expand the market beyond traditional healthcare settings.

The integration of AI-powered symptom tracking apps, smartphone-based anterior segment imaging, and connected diagnostic devices further strengthens this opportunity. These technologies improve patient engagement, treatment adherence, remote monitoring, and telemedicine support, while creating recurring revenue opportunities beyond one-time capital equipment sales.

Product Type Insights

Thermal pulsation devices are projected to account for around 38% of the market revenue in 2026, driven by the widespread clinical adoption of Johnson & Johnson Vision’s LipiFlow Thermal Pulsation System for treating Meibomian gland dysfunction (MGD)-related evaporative dry eye. The device has a strong clinical evidence base, and in 2023, the company reported that a single LipiFlow treatment improved Meibomian gland function and dry eye symptoms for up to three months.

Light-based therapy devices are expected to register the fastest growth during the forecast period. Intense Pulsed Light (IPL) therapy improves Meibomian gland function by reducing abnormal eyelid blood vessels, enhancing gland secretion, and lowering bacterial load and Demodex mites. In 2021, Lumenis received FDA clearance for OptiLIGHT, the first IPL device approved for MGD-associated dry eye disease, with clinical studies demonstrating improved gland function and symptom relief.

Technology Insights

Thermal therapy technologies are projected to account for around 42% of the market revenue in 2026, driven by the widespread use of professional thermal pulsation systems and home-use eyelid warming devices for treating Meibomian gland dysfunction (MGD). These technologies help liquefy and clear blocked gland secretions across different stages of the disease. Sight Sciences has reported increasing adoption of its TearCare® System, which improves Meibomian gland function in patients with MGD-related dry eye.

Smart diagnostic and monitoring devices are expected to be the fastest-growing technology segment. Growth is supported by the rising use of meibography imaging systems, interferometry-based tear film analyzers, and AI-powered diagnostic platforms that enable objective diagnosis and treatment monitoring. Topcon Healthcare has expanded adoption of its MYAH platform, which integrates meibography with dry eye assessment tools for comprehensive evaluation of Meibomian gland health.

End-user Insights

Hospitals and eye care clinics are projected to account for around 55% of the market revenue in 2026, driven by the concentration of advanced dry eye disease (DED) diagnostic and treatment devices in specialized healthcare facilities. High patient volumes, dedicated infrastructure, and trained professionals support the widespread adoption of these technologies. In 2025, Global Eye Hospital launched a dedicated Dry Eye Clinic equipped with LipiView®, LipiFlow®, and IPL technologies, highlighting the growing use of advanced DED solutions in specialized eye care centers.

Home care settings are expected to witness the fastest growth during the forecast period. Growth is driven by increasing availability of home-use thermal eyelid warming devices, handheld Meibomian gland expression tools, and connected symptom-monitoring applications that support ongoing treatment between clinic visits. Bruder Healthcare has continued to expand the adoption of its Bruder Moist Heat Eye Compress, a widely recommended home-use thermal therapy device for managing Meibomian gland dysfunction (MGD) and dry eye disease.

North America Dry Eye Disease Treatment Devices Market Trends

North America is projected to hold around 40% of the market revenue in 2026. Growth is driven by the high prevalence of clinically diagnosed dry eye disease (DED). The region also benefits from a well-established ophthalmology and optometry infrastructure and the presence of leading manufacturers such as Johnson & Johnson Vision and Lumenis Ltd.

U.S. Dry Eye Disease Treatment Devices Market Insights

The U.S. is projected to account for around 85% of the North American market in 2026. It represents the world's largest market for advanced dry eye disease (DED) treatment devices. Growth is driven by increasing recognition of Meibomian gland dysfunction (MGD) as a key cause of dry eye and strong clinical evidence supporting LipiFlow and IPL therapies.

Canada Dry Eye Disease Treatment Devices Market Insights

Canada is projected to account for around 10% of the regional market in 2026. Growth is supported by increasing recognition of dry eye disease (DED), expanding optometry practice capabilities, and rising adoption of thermal pulsation and IPL therapies for managing Meibomian gland dysfunction (MGD).

Europe Dry Eye Disease Treatment Devices Market Trends

Europe is projected to account for around 28% of the market revenue in 2026, making it the second-largest regional market. Growth is driven by advanced ophthalmology infrastructure, supportive CE-marked regulatory frameworks, and increasing adoption of evidence-based Meibomian gland-targeted therapies.

Germany Dry Eye Disease Treatment Devices Market Trends

Germany is projected to account for around 24% of the Europe market in 2026. Growth is driven by its advanced ophthalmology infrastructure, high digital screen usage, and supportive private health insurance coverage for office-based dry eye disease (DED) treatments.

U.K. Dry Eye Disease Treatment Devices Market Trends

The U.K. is projected to account for around 18% of the European market in 2026. Growth is supported by increasing recognition of dry eye disease (DED), expanding adoption of evidence-based MGD therapies, and the rapid growth of premium dry eye care services in the private ophthalmology and optometry sector.

Asia Pacific Dry Eye Disease Treatment Devices Market Trends

Asia Pacific is expected to be the fastest-growing regional market. Growth is driven by high digital device usage, rapidly aging populations, expanding ophthalmology infrastructure, and rising disposable incomes that support adoption of advanced dry eye disease (DED) treatments.

Japan Dry Eye Disease Treatment Devices Market Trends

Japan is projected to be the most mature dry eye disease treatment devices market in Asia Pacific, accounting for around 20% of the regional market in 2026. Growth is supported by early recognition of DED as a chronic condition and the adoption of Meibomian gland imaging and thermal therapy as part of standard ophthalmology practices.

China Dry Eye Disease Treatment Devices Market Trends

China is projected to account for around 45% of the Asia Pacific market revenue in 2026. Growth is driven by the country’s large digital device user base, rising DED prevalence among the aging population, and the expansion of private ophthalmology clinics offering advanced device-based treatments.

The global dry eye disease treatment devices market includes diversified ophthalmic device and pharmaceutical companies, specialized DED technology providers, and diagnostic imaging companies offering solutions for diagnosis and treatment management.

Johnson & Johnson Vision, through its LipiFlow Thermal Pulsation System, holds a strong position in the thermal pulsation segment. Its leadership is supported by extensive clinical evidence, physician training programs, and integration with J&J’s broader ophthalmology ecosystem. Alcon Laboratories competes in the thermal pulsation segment with its iLux MGD Treatment System, a compact handheld thermal expression device designed to offer a lower-cost alternative and improve adoption among practices with limited capital investment capacity.

Key Industry Developments:

• In June 2026, Bausch + Lomb Corporation launched Blink Triple Care Preservative Free eye drops in the U.S., expanding its dry eye care portfolio. The company introduced the preservative-free formulation in a multi-dose bottle to provide instant and long-lasting relief for dry eye symptoms while enhancing patient convenience.
• In July 2025, Alcon announced the U.S. commercial launch of TRYPTYR® (acoltremon ophthalmic solution) 0.003% following FDA approval, expanding treatment options for patients with Dry Eye Disease (DED) and enabling eye care professionals to prescribe the therapy nationwide.